Physician profile
John L Behm
NPI 1437151677
$2,187.93
in general payments reported to CMS, 2019-2025
35 companies · $17.06 in 2025
The $17.06 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $121 · 2021: $377 · 2022: $884 · 2023: $522 · 2025: $17.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $506.52 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $393.77 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $253.07 | 2021-2023 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $217.98 | 2019-2023 | Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $113.21 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $103.50 | 2019-2023 | Eliquis |
| Pfizer INC. | $101.54 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $93.55 | 2022-2023 | Seglentis |
| Amarin Pharma, INC. | $63.16 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $60.46 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $59.77 | 2022 | |
| Alkermes, INC. | $57.84 | 2022-2023 | Vivitrol |
| Daiichi Sankyo INC. | $56.18 | 2022-2023 | Injectafer |
| Protega Pharmaceutials INC | $51.30 | 2022-2023 | Roxybond |
| Lilly USA, LLC | $50.48 | 2019-2020 | |
| Corium, LLC | $48.29 | 2022-2023 | Azstarys |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $45.70 | 2022-2023 | |
| Abbott Laboratories | $41.67 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $36.78 | 2023 | Xarelto |
| Amgen INC. | $32.62 | 2022 | |
| Neos Therapeutics, Lp | $30.27 | 2021-2022 | |
| Gilead Sciences, INC. | $28.92 | 2019 | |
| Horizon Therapeutics Plc | $26.44 | 2019-2020 | |
| Medtronic, INC. | $24.51 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $21.62 | 2023 | Quviviq |
| Amneal Pharmaceuticals LLC | $21.08 | 2022 | |
| Inari Medical, INC. | $20.95 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $18.37 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $17.06 | 2025 | Farxiga |
| Merck Sharp & Dohme LLC | $15.06 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.86 | 2021 | |
| Circassia INC. | $14.60 | 2019 | |
| Ibsa Pharma INC. | $14.24 | 2022 | |
| Nevro Corp. | $14.20 | 2021 | |
| Optinose US, INC. | $13.59 | 2021 | |
| Philips North America LLC | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Behm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.